CERENOME, INC. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cerenome presented interim ReSPECT-LM data for 10 patients receiving repeated intraventricular REYOBIQ (rhenium Re186 obisbemeda) for leptomeningeal metastases. No dose-limiting toxicities or treatment discontinuations occurred; one patient received three 26.4 mCi doses (79.2 mCi cumulative, exceeding prior single-dose maximum of 75 mCi); radiation delivery was consistent (median 8% variation); 0/5 evaluable patients showed LM progression at 3–6 months, 1/4 by 9 months. Company targets Phase 2 randomized study in 2027.
Why this rating
Early-stage clinical validation of lead asset in a $31.9M company; tolerability and consistent dosimetry de-risk next phase, supporting 2027 Phase 2 initiation critical to future value.
Tradability signal
NO TRADE
No trade: positive news with only -3.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.04% over 4 hrs, n=508). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.96 ▲ 0.83% | at our read · unknown $0.95 | +10 min · unknown $0.92 ▼ 3.50% | +30 min · unknown $0.87 ▼ 9.36% | +1 hr · unknown $0.75 ▼ 21.47% | +4 hrs · unknown $0.75 ▼ 21.25% |
The stock had already moved -0.82% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.